Abbott Laboratories Corporation

Abbvie Inc.

Sharps Associates

Martin Winn

Bryan K Sorensen

Hwan-soo Jae

Steven Armen Boyd

James T Link

Thomas W Von Geldern

Andrew Stewart Tasker

Jyoti R Patel

Hong Yong

Qi Shuai

Jeffrey A Kester

Charles W Hutchins

Gang Liu

Jeffrey J Rohde

Michael E Brune

Peer Jacobson

Kenneth J Henry

John F DeBernardis

Steven J Wittenberger

Steven A King

Bruce G Szczepankiewicz

Jiahong Wang

Lynne E Rueter

Kaitlin E Browman

R Scott Bitner

Vince S Yeh

Marina Pliushchev

David L Arendsen

Dariusz Wodka

Jaroslav Kyncl

Jurgen Dinges

Marina I Strakhova

Steven Fung

Yixian Chen

Zhili Xin

Raj Kumar Razdan

Zhonghua Pei

Haldean Cloyce Dalzell

Daniel Ambrose Dunnigan

Joyce Ruth Krei

Tom Von Geldern

Biswanath De

Philip R Kym

John K Pratt

Karla Drescher

Karsten M Wicke

Saul H Rosenberg

Anthony K Fung

Daniel Joseph Kerkman

Irini Akritopoulou-Zanze

Fatima Z Basha

David J Madar

Ravi Kurukulasuriya

Peter Hadley Jones

Diane M Yamamoto

Thomas M Zydowsky

Kazumi Shiosaki

John J Kyncl

Tom W Von Geldern

Carl W Nordeen

Benjamin C Lane

Jehrod Brenneman

Hwan-Soo Jae

Gui-Dong Zhu

Kresna Hartandi

Indrani W Gunawardana

Sheldon Wang

John K Lynch

Michael A Staeger

Jennifer C Freeman

Kenneth P Spina

Robert J Padley

Peter Handley Jones

Todd J Janus

Kimba L Ashworth

Yixian Long

Thomas W Vongeldern

A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-&#x3b2;-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Treatment of central nervous system disorders

The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Endothelin antagonists

A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Growing community of inventors

Deerfield, IL, United States of America

Martin Winn